A new approach to protein degradation – At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches.
Location: United Kingdom, Scotland, Chapelhall
Total raised: $60.5M
Investors 5
| Date | Name | Website |
| - | BioMotiv | biomotiv.c... |
| - | BioCity | biocity.co... |
| 17.03.2021 | Gilde Heal... | gildehealt... |
| - | Forbion | forbion.co... |
| - | Advent Lif... | adventls.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.03.2021 | Series B | $53M | Gilde Heal... |
| 07.04.2020 | Series A | $7.5M | - |
Mentions in press and media 8
| Date | Title | Description |
| 28.05.2024 | Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium | Cambridge, UK, May 23, 2024 – Amphista Therapeutics (“Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the unveiling of a new mechanism of action for the degradation of BRD9, an emerging... |
| 24.01.2024 | Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders | Cambridge, UK, January 24th, 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the achievement of two compelling new data sets with its nex... |
| 24.01.2024 | Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders | • First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader • Deep degradation of target protein is achieved in a rapid, sustained, and highly selec... |
| 13.12.2022 | Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases | Cambridge, UK – December 13, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced a Series B extension investment by the Dementia Discovery Fund (DDF). The investment is in... |
| 17.03.2021 | Amphista Therapeutics raises $53M in Series B round co-led by Gilde Healthcare to advance next generation targeted protein degradation assets | Glasgow, UK - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the closing of a $53 million (£38 million) Series B financing round from an investor syndicate co-led by Gilde H... |
| 17.03.2021 | Amphista Therapeutics Raises $53M in Series B Funding | Amphista Therapeutics, a Glasgow, Scotland, UK-based leader in next generation targeted protein degradation (TPD) approaches, closed a $53m (£38m) Series B financing round. The round was co-led by Forbion and Gilde Healthcare with participa... |
| 08.04.2020 | Daily funding roundup - April 7th, 2020 | Cyolo has raised $4.2M; Amphista Therapeutics secured $7.5M; Neat landed $11M Cyolo: Cyolo is a unified connectivity platform. Cyolo has raised $4.2 million in seed funding led by Flint Capital, with participation from Global Founders Capit... |
| 07.04.2020 | Amphista Therapeutics Raises $7.5M in Series A Funding | Amphista Therapeutics, a Glasgow, Scotland-based biopharmaceutical company, closed a USD $7.5m Series A funding round. The round was led by Advent Life Sciences with participation from the Scottish Investment Bank, the European Investment F... |